FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number: 3235-028										
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Shukla Sanjay													5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
				٦			.,					<u> </u>	Director			10% Ov	/ner	
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/26/2020								below)			Other (s	pecify	
3545 JOHN HOPKINS COURT, SUITE #250				ľ	03/20/2020							President and			CEO			
(Street)	EGO C	A	92121								Line)	X Form filed by One Reporting Person						
(City)	(S	state)	(Zip)		Form filed by More than One Reporting Person									ting				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date				action 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4) 5)		d (A) or r. 3, 4 and	5. Amoun Securities Beneficia Owned Fo	s lly ollowing	Form (D) or	orm: Direct D) or Indirect	7. Nature of Indirect Beneficial Ownership					
								Code	v	Amount	(A) or (D)	Price	Transacti (Instr. 3 a	on(s)			(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code 8)		Derivative Securities Acquired or Dispos	Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,		6. Date Exercisa Expiration Date (Month/Day/Year		e of Securities		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	ion(3)	,		
Employee Stock Option (right to buy)	\$4.06	05/26/2020		A		73,142 ⁽¹⁾		(2)		05/26/2030	Common Stock	73,142	\$0.00	73,14	12	D		

Explanation of Responses:

- 1. The option grant was originally intended for 80,000 shares. However, that size of grant was in excess of an annual grant limit in the Issuer's equity plan and, as a result, the portion of the award that was in excess of the plan limit was disgorged.
- 2. 50% of the shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning June 26, 2020, such that these shares will be fully exercisable on May 26, 2024; 25% of the shares subject to this option will vest on May 26, 2021 if and only if a clinical development milestone is achieved by September 30, 2020; and the remaining 25% of the shares will vest on May 26, 2021 if and only if an additional clinical development milestone is achieved by September 30, 2020.

Remarks:

Nancy E. Denyes, Attorney-in-

Fact

03/09/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.